Tesamorelin
FDA-approved GHRH analog for specific clinical indications.
Research Areas
Scientific Background
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been studied for its ability to stimulate natural growth hormone production.
Deep Dive: How It Works
Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs, triggering cAMP-mediated GH synthesis and secretion in a pulsatile (wave-like) pattern that mimics natural physiology. The pulsatile release is important because continuous GH elevation desensitizes receptors and disrupts IGF-1 feedback. The trans-3-hexenoic acid modification at the N-terminus protects against DPP-IV enzymatic degradation, extending its bioactive window. Downstream effects include: (1) IGF-1 elevation → protein synthesis, cell repair; (2) Lipolysis activation → visceral fat mobilization; (3) Hepatic fat oxidation → reduced liver fat content; (4) Potential neurological effects via GH/IGF-1 signaling in the CNS.
Key Insight
Tesamorelin is the ONLY FDA-approved peptide in this collection. Its approval for HIV lipodystrophy provides a strong safety dataset from Phase 3 trials. The cognitive research is particularly interesting — it suggests GH/IGF-1 signaling may influence brain function beyond just body composition.
Optimization & Cofactors
Published research on compounds that support this peptide's mechanisms
Cofactor information is compiled from published nutritional and biochemical research. This is educational content, not supplementation advice. Consult a qualified healthcare provider.
Glycine
3g before bedEnhances sleep quality and potentiates nocturnal GH release
Glycine improves slow-wave sleep — GH secretion phase (Bannai et al., 2012)
Zinc
25mg with lunchRequired for GH-IGF-1 axis and pituitary GH synthesis
Zinc deficiency impairs GH secretion (Prasad, 2013)
Vitamin D3
2000-5000 IU morning with fatPituitary D receptors support GH production pathways
Ameri et al. (2013) found D sufficiency correlates with optimal IGF-1
Arginine
Before bed on empty stomachMay potentiate GH release through somatostatin suppression
Alba-Roth et al. (1988) showed arginine stimulates GH via somatostatin suppression
Compatibility & Stacking Guide
Research on combining peptides based on published mechanisms
Compatibility information is based on published mechanisms of action. No clinical trials have validated most combinations in humans. This is educational content only.
Compatible Compounds (Research-Based)
Use Separately (Research-Based)
Both target GHRH pathway — combining risks receptor desensitization
Exogenous GH suppresses pituitary, counteracting Tesamorelin mechanism
Timing Guide from Published Research
FDA-approved Egrifta: once-daily subcutaneous, typically morning or before bed, on empty stomach. As the ONLY FDA-approved peptide here, its dosing protocol is most well-established.
Published Clinical Study Protocols
Data from peer-reviewed publications and registered clinical trials
These protocols are cited from published research for educational purposes only. They do not constitute recommendations. All research must be conducted under appropriate institutional oversight.
HIV Lipodystrophy Phase 3 (FDA Approval Study)
Falutz et al., New England Journal of Medicine, 2007
2mg subcutaneous injection daily for 26 weeks in HIV+ patients with abdominal lipodystrophy
Visceral adipose tissue reduced ~15-18%. Improved body image scores. Reduced triglycerides and total cholesterol.
Cognitive Effects in Older Adults
Friedman et al., Archives of Neurology, 2012
20 weeks of administration in healthy older adults (with and without mild cognitive impairment)
Improved executive function (response inhibition, set-shifting). Companion neuroimaging showed increased brain GABA and decreased myo-inositol (Alzheimer's-associated marker).
NAD+ Repletion via NR in Aging
Stanley et al., Various publications
Assessment of hepatic fat fraction using MRI spectroscopy during tesamorelin treatment
Reduced liver fat content, with potential prevention of fibrosis progression in NAFLD patients.
Synergy & Cofactor Research
How this compound interacts with other molecules in research
Tesamorelin + Adequate Sleep
GH secretion peaks during slow-wave (deep) sleep. Tesamorelin enhances GHRH signaling, which is itself linked to improved slow-wave sleep duration.
GHRH receptor activation is associated with slow-wave sleep induction. Since 70% of daily GH secretion occurs during deep sleep, optimizing sleep quality amplifies the pituitary's response to tesamorelin.
GHRH Analog vs. Direct GH
Direct GH injection provides supraphysiological levels that suppress pituitary function. Tesamorelin works WITH the pituitary, preserving natural feedback loops.
GHRH analogs stimulate the pituitary to release GH on its own schedule, maintaining IGF-1 feedback sensitivity. Direct GH bypasses the pituitary, potentially causing receptor desensitization and pituitary suppression.
Purity & Provenance
Why quality matters for research validity
FDA-approved compound (Egrifta/Egrifta SV) with established pharmaceutical standards. Research-grade should meet ≥98% HPLC. Its 44-amino acid sequence with trans-3-hexenoic acid modification requires mass spec verification.
Areas of Investigation
Laboratory Information
Technical specifications for research settings
This compound is intended for qualified scientific research only. Not for human or veterinary use. Not for diagnostic or therapeutic applications. Researchers must comply with all applicable regulations in their jurisdiction.
Store at 2-8°C per manufacturer guidelines.
Lyophilized powder
Pharmaceutical grade
FDA-approved compound. Research use should follow appropriate protocols.
Deepen Your Research
Published literature and clinical trial registries
Published Literature
Extensive clinical trial data exists for Tesamorelin in its approved indication.
Regulatory Classification
Tesamorelin (Egrifta®) is FDA-approved specifically for HIV-associated lipodystrophy. All other uses are off-label and require appropriate medical oversight. This is a prescription medication.
Important Research Notice
This information is compiled from scientific literature for educational purposes only. This website does not sell, distribute, or recommend any compounds for human use. All compounds discussed are for qualified research purposes only.